Trial Profile

Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary)
Indications Carcinoma; Cervical cancer; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours; Uterine cancer
Focus Therapeutic Use
Acronyms MoST Addendum 8

Most Recent Events

06 Jun 2023 Results from the Molecular Screening and Therapeutics (MoST) Program substudy, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 8 patients have been enrolled
08 Jun 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com